Related Experiment Video

Updated: Mar 16, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer

Ramon Andrade De Mello1, Davi J J Liu, Pedro N Aguiar

  • 1Department of Biomedical Sciences and Medicine, University of Algarve, Campus de Gambelas, Ala nascente, Edifício 7, 3º Andar, 8005-139, Faro, Portugal. ramondemello@gmail.com.

Recent Patents on Anti-Cancer Drug Discovery
|August 6, 2016
PubMed
Abstract

Insights

Targeted therapies for non-small cell lung cancer (NSCLC) with EGFR or ALK mutations, including novel drugs and patents, offer improved outcomes. Understanding molecular profiles is key for effective NSCLC treatment strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
  • Recent advancements have focused on targeted therapies for specific driver mutations in NSCLC.

Purpose of the Study:

  • To review the latest therapeutic strategies for NSCLC harboring EGFR and ALK mutations.
  • To identify and discuss relevant clinical studies and promising patents in NSCLC treatment.

Main Methods:

  • A comprehensive literature search was conducted using the PubMed database.
  • The search focused on clinical trials of EGFR therapies and novel patents related to NSCLC diagnosis and treatment.
  • Five relevant patents were selected for further discussion.

Main Results:

  • The identification of epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements has transformed NSCLC classification and treatment.
  • Acquired resistance to targeted therapies presents a significant challenge, driving the development of new drug options.
  • Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) and ALK inhibitors have significantly improved outcomes in advanced NSCLC.

Conclusions:

  • Targeted therapies, including EGFR TKIs and ALK inhibitors, have revolutionized the management of advanced NSCLC.
  • Personalized treatment approaches based on the molecular profile of NSCLC are essential for optimal patient outcomes.
  • Ongoing research and development of novel drugs aim to overcome resistance and further enhance treatment strategies for NSCLC.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Cancer Therapies02:49

Cancer Therapies

2.9K